Drugs / Recombinant Antithrombin
Recombinant Antithrombin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01913444 | Jul 2013 → Oct 2014 | — | Children's Hospital Los Angeles | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01547728 | Feb 2012 → Feb 2014 | thrombophilia | Mayo Clinic | Terminated | No outcome recorded Stop: Enrollment |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-04-25 | Knight Therapeutics (USA) Inc | Knight Receives NOD from Health Canada for ATryn(R) knighttx.com ↗ |
| 2015-08-06 | Knight Therapeutics (USA) Inc | Knight and LFB S.A. Announce Filing of New Drug Submission for ATryn(R) knighttx.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant antithrombin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01547728 ↗ |
| Known as | ATRYN | “recombinant antithrombin (rhAT, ATRYN ®)” NCT01547728 ↗ |
| Known as | rAT | “recombinant antithrombin (rAT) (ATRYN)” NCT01547728 ↗ |
| Known as | rhAT | “recombinant antithrombin (rhAT, ATRYN ®)” NCT01547728 ↗ |
| Action | Inhibit | “only inhibition of thrombin and factor Xa by AT has physiologic and clinical significance” NCT01547728 ↗ |
| Modality | Protein / enzyme biologic | “recombinant, human antithrombin (rhAT, ATRYN ®)” NCT01547728 ↗ |
| Route | Intravenous | “an intravenous bolus” NCT01547728 ↗ |